Neuropeptides (VIP, alpha-MSH, CGRP) promote immune tolerance by generating regulatory T cells and suppressing inflammatory responses — a novel neuroimmune pathway for controlling autoimmunity and transplant rejection.
Key findingNeuropeptides including VIP, alpha-MSH/KPV, and CGRP promote immune tolerance through generation of regulatory T cells (Tregs) and suppression of pro-
What the researchers found
Neuropeptides including VIP, alpha-MSH/KPV, and CGRP promote immune tolerance through generation of regulatory T cells (Tregs) and suppression of pro-inflammatory dendritic cell activation — a novel immunosuppressive pathway with therapeutic potential for autoimmunity and transplantation.
Why it matters
Relevant for neuropeptides, immune-function, inflammation.
How the study worked
review study on neuropeptides, immune-function.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 1(4), 400-9
Citation
Ganea, Doina; Gonzalez-Rey, Elena; Delgado, Mario. (2006). A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 1(4), 400-9.